Spots Global Cancer Trial Database for Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Official Title: A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy, in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Study ID: NCT04789408
Conditions
Study Description
Brief Summary: The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Stanford Cancer Center, Stanford, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Cleveland Clinic, Cleveland, Ohio, United States
The Ohio State University Wexner Medical Center/James Cancer Hospital, Columbus, Ohio, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Institut Paoli-Calmettes, Marseille, , France
CHU de Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, , France
Contact Details
Name: Kite Study Director
Affiliation: Kite, A Gilead Company
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
